$JOBY

Should You Trim Or Add To Your Joby Aviation Position Now?

Joby Aviation (JOBY) stock has fallen 70% in the past year. The company reported $38.6M in Q2 2026 revenue, mainly from its Blade business, and raised its 2026 revenue forecast to $115M-$125M. Joby has $2.3B in cash but faces high operating losses and a recent $100M IP lawsuit judgment. It plans to spend $385M-$415M in the second half of 2026 and acquired Resonant Sciences for $500M. The stock trades at 40x sales, with no meaningful P/E due to losses.

Original reporting
Published Oct 17, 2026, 2:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 17, 2026, 3:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Should You Trim Or Add To Your Joby Aviation Position Now? — source image
Decision brief

The 30-second read

$JOBYBearishMed
01

Why it matters

The article’s core trade question is whether Joby can fund certification and ramp through 2H26 and beyond, while absorbing legal damages and still reaching first passenger service in 2026.

02

Market read

For traders, the combination of cash runway math, raised revenue guidance, and a large damages award changes the risk-reward for holding or adding to JOBY ahead of the 2026 launch milestone.

03

What to watch

The article does not quantify how much of the Blade-related revenue is recurring versus transitional, nor does it detail appeal prospects or payment terms for the damages award, both of which can materially change downside risk.

Relevance 4/10Novelty 5/10Timing: decision framing for positioning now, with catalysts tied to 2H26 cash use and 2026 first-passenger target

Background

Joby is an eVTOL developer with heavy operating losses and a commercialization timeline dependent on certification, manufacturing ramp, and passenger launch.

Company-level read

Ticker impact

$JOBYBearishMedium confidence
Context

Article frames Joby’s funding runway risk, citing $2.3B cash, 2026 revenue forecast raise, and a $100M+ IP damages verdict.

Expected impact

Likely choppy-to-downward bias as investors weigh ongoing operating losses and the IP damages over the path to first passenger service in 2026.

Evidence & confidence

The piece highlights sustained losses, cash burn expectations for 2H26, and a large damages award, which together can pressure valuation despite forecast improvement and remaining cash.

Market effects

Reinforces capital intensity and legal/IP risk in the eVTOL commercialization race, which can affect sentiment across early-stage aerospace/aviation tech.

Limited direct regional spillover; primarily impacts US-listed eVTOL risk appetite.

Moderate, as eVTOL commercialization timelines and litigation outcomes influence global investor perception of the sector’s near-term viability.

Counterpoint

The raised 2026 revenue forecast and stated target to carry first passengers in 2026 suggest execution momentum, and the cash balance may be sufficient to absorb damages while certification progress continues.

Key entities

  • Joby Aviation

    Subject of the article, discussed via cash position, 2026 revenue forecast, operating losses, and an IP damages verdict.

  • Aerosonic

    Parts supplier sued Joby; jury verdict reportedly awarded damages against Joby.

  • TransDigm Group

    Owner of Aerosonic, referenced as the supplier’s parent.

  • Resonant Sciences

    Defense technology company Joby agreed to buy for about $500M, affecting cash runway.

  • Blade

    Passenger business Joby acquired, cited as primary source of Q2 revenue.

Related articles

$JOBYMed

4 High-Risk Stocks Built for Big Returns

Joby Aviation aims to be a transportation-as-a-service company with its eVTOL aircraft, making progress with FAA-compliant and autonomous technology. Viking Therapeutics is developing obesity drug VK2735, showing promising weight loss data in trials. Both companies are high-risk, high-reward investments.

$JOBYMed

Why Did ASTS, CIFR, JOBY Stocks Plunge To 52-Week Lows Today?

Joby Aviation (JOBY) reported a larger-than-expected Q2 loss of $0.25 per share, raising concerns about its financial resources. Barclays downgraded JOBY to 'Underweight', questioning its market potential and production capacity. ASTS, CIFR, and JOBY stocks have fallen 23-62% this year. Retail sentiment remains bullish despite the downturn.

$JOBYMed

What Just Happened To Joby Stock?

Joby Aviation (JOBY) stock fell 68.4% in the year to October 12, 2026, despite the S&P 500 gaining 20.5%. Key events included a Goldman Sachs Sell rating, broader market adjustments, and a $116.9M damages ruling. Joby's Q2 2026 revenue was $39M, with a net loss of $245M. The company has $2.3B in cash and plans to spend $385M-$415M in the second half of 2026.